Boston Scientific Corporation (NYSE:BSX – Get Free Report) hit a new 52-week low during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $77.86 and last traded at $75.5250, with a volume of 8794500 shares traded. The stock had previously closed at $91.62.
Specifically, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on the stock. UBS Group restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, December 17th. National Bankshares set a $115.00 price target on shares of Boston Scientific in a research note on Monday. Royal Bank Of Canada lifted their price target on shares of Boston Scientific from $125.00 to $130.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. TD Cowen reiterated a “buy” rating on shares of Boston Scientific in a report on Monday. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $121.84.
More Boston Scientific News
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Q4 beat on both EPS and revenue; revenue grew ~15.9% year-over-year, and margins improved — the underlying quarter was strong, showing continued organic growth across several franchises. Boston Scientific announces results for fourth quarter and full year 2025
- Neutral Sentiment: Analyst coverage and the company’s earnings materials/earnings call provide detail for valuation and segment trends — useful for investors who want to dig into segment-level drivers and management’s assumptions. Q4 2025 Earnings Call Transcript
- Negative Sentiment: Management’s FY‑2026 guidance was modestly below or roughly in line with Street expectations (FY EPS range and revenue range came in light enough to reset growth assumptions), and Q1 guidance was cautious — that outlook is the main driver of the selloff. Boston Scientific shares slide on cautious 2026 revenue forecast
- Negative Sentiment: Electrophysiology (one of Boston Scientific’s higher-growth, higher-profile segments) underperformed vs. expectations, which worried investors about near-term growth momentum in a key franchise. Boston Scientific hits an 18-month low on a ‘sore spot’ for its most hyped device
- Negative Sentiment: Unusually large put-option activity and heavy trading signaled short-term bearish positioning and hedging, amplifying downside pressure. BSX Earnings: Boston Scientific Stock Plunges on Weak Guidance
- Negative Sentiment: CEO insider selling (large block disclosed) adds to near-term negative sentiment even though insider transactions can be for many reasons. Insider sale SEC filing
Boston Scientific Stock Performance
The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average price of $94.37 and a 200 day moving average price of $99.13. The firm has a market capitalization of $111.92 billion, a PE ratio of 40.37, a price-to-earnings-growth ratio of 1.63 and a beta of 0.67.
Boston Scientific (NYSE:BSX – Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in BSX. Catalyst Financial Partners LLC lifted its holdings in Boston Scientific by 16.0% during the 4th quarter. Catalyst Financial Partners LLC now owns 9,478 shares of the medical equipment provider’s stock worth $904,000 after buying an additional 1,305 shares in the last quarter. Ameritas Advisory Services LLC increased its position in shares of Boston Scientific by 264.2% during the fourth quarter. Ameritas Advisory Services LLC now owns 7,269 shares of the medical equipment provider’s stock worth $693,000 after acquiring an additional 5,273 shares during the period. Atlantic Union Bankshares Corp raised its stake in shares of Boston Scientific by 1,962.1% in the fourth quarter. Atlantic Union Bankshares Corp now owns 598 shares of the medical equipment provider’s stock valued at $57,000 after acquiring an additional 569 shares in the last quarter. World Investment Advisors boosted its holdings in Boston Scientific by 2.2% in the fourth quarter. World Investment Advisors now owns 19,365 shares of the medical equipment provider’s stock valued at $1,777,000 after purchasing an additional 411 shares during the period. Finally, Rock Point Advisors LLC acquired a new position in Boston Scientific during the 4th quarter worth $2,209,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.
Featured Articles
- Five stocks we like better than Boston Scientific
- The day the gold market broke
- Buy this Gold Stock Before May 2026
- Forget AI, This Will Be the Next Big Tech Breakthrough
- New gold price target
- Trump Planning to Use Public Law 63-43: Prepare Now
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
